BSE Live
Mar 23, 16:01Prev. Close
37.01
Open Price
36.76
Bid Price (Qty.)
35.28 (2)
Offer Price (Qty.)
35.28 (15028)
NSE Live
Mar 23, 15:59Prev. Close
36.99
Open Price
36.59
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
35.33 (4339)
| Balance Sheet of Morepen Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 89.96 | 89.96 | 89.96 | 89.96 | 89.96 | |
| Total Share Capital | 209.61 | 209.61 | 209.61 | 209.61 | 209.61 | |
| Reserves and Surplus | 103.47 | 114.65 | 120.81 | 143.48 | 167.65 | |
| Total Reserves and Surplus | 103.47 | 114.65 | 120.81 | 143.48 | 167.65 | |
| Total Shareholders Funds | 313.08 | 324.26 | 330.42 | 353.09 | 377.26 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 62.22 | 74.65 | 94.49 | 113.89 | 128.69 | |
| Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Long Term Liabilities | 1.76 | 2.05 | 2.09 | 2.43 | 2.42 | |
| Long Term Provisions | 8.71 | 7.35 | 6.78 | 4.69 | 3.75 | |
| Total Non-Current Liabilities | 72.69 | 84.05 | 103.36 | 121.01 | 134.86 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 2.23 | 1.19 | 0.00 | 0.00 | 0.00 | |
| Trade Payables | 78.55 | 66.75 | 54.90 | 63.59 | 57.32 | |
| Other Current Liabilities | 32.82 | 30.91 | 52.14 | 43.20 | 44.68 | |
| Short Term Provisions | 0.84 | 0.73 | 0.68 | 1.82 | 1.74 | |
| Total Current Liabilities | 114.44 | 99.58 | 107.72 | 108.61 | 103.74 | |
| Total Capital And Liabilities | 500.21 | 507.89 | 541.50 | 582.71 | 615.86 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 243.43 | 288.88 | 330.59 | 373.57 | 416.58 | |
| Intangible Assets | 0.50 | 0.59 | 0.32 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 243.93 | 289.47 | 330.91 | 373.57 | 416.58 | |
| Non-Current Investments | 117.94 | 117.94 | 121.81 | 121.81 | 121.91 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 33.93 | 1.75 | 1.58 | 1.55 | 1.30 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 395.80 | 409.16 | 454.30 | 496.93 | 539.79 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 35.36 | 32.91 | 36.75 | 38.01 | 33.61 | |
| Trade Receivables | 48.45 | 40.09 | 36.59 | 33.13 | 27.73 | |
| Cash And Cash Equivalents | 8.60 | 8.07 | 4.72 | 3.96 | 2.34 | |
| Short Term Loans And Advances | 8.89 | 14.07 | 6.01 | 9.00 | 9.61 | |
| OtherCurrentAssets | 3.11 | 3.59 | 3.13 | 1.68 | 2.78 | |
| Total Current Assets | 104.41 | 98.73 | 87.20 | 85.78 | 76.07 | |
| Total Assets | 500.21 | 507.89 | 541.50 | 582.71 | 615.86 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 32.76 | 33.49 | 34.90 | 8.12 | 4.88 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 63.07 | 46.91 | 51.81 | 32.66 | 25.98 | |
| Stores, Spares And Loose Tools | 5.12 | 1.71 | 5.05 | 6.37 | 8.61 | |
| Trade/Other Goods | 5.12 | 1.71 | 5.05 | 6.37 | 8.61 | |
| Capital Goods | 0.18 | 0.00 | 0.63 | 0.24 | 0.16 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 1.61 | 3.00 | 1.81 | 1.44 | 0.64 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 106.15 | 108.98 | 98.60 | 81.50 | 50.28 | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | -- | -- | -- | -- | -- | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 117.94 | 117.94 | 121.81 | 121.81 | 121.91 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
16.03.2026
Morepen Lab Consolidated December 2025 Net Sales at Rs 484.16 crore, up 6.93% Y-o-Y
20.02.2026
Morepen Lab Consolidated December 2025 Net Sales at Rs 484.16 crore, up 6.93% Y-o-Y
19.02.2026
Morepen Lab Standalone December 2025 Net Sales at Rs 457.57 crore, up 13.47% Y-o-Y
26.11.2025
Morepen Lab Consolidated September 2025 Net Sales at Rs 411.58 crore, down 5.97% Y-o-Y
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth